- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04673591
Effects of Tregalizumab on Allergen-induced Airway Responses and Airway Inflammation in Asthmatic Patients (Tregulaire)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will consist of a screening phase, a treatment phase and a follow-up phase.
Eligible subjects will undergo a bronchial allergen provocation (BAP) with mite allergen to assess the asthmatic response before and after treatment. Subjects will be randomized to two parallel treatment groups. Each subject will be treated weekly over 12 weeks either with test product or with the reference product (placebo).
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Frankfurt, Germany
- Medaimun GmbH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Willing and able to give written informed consent.
- Male or female subject aged 18 to 65 years (both inclusive).
- Established diagnosis of mild controlled allergic asthma (GINA 2019) and history of allergic bronchial asthma for at least 1 year.
- BMI of 18.0 to 30.0 (both inclusive).
- Non-smoker (all substances).
- Specific IgE to HDM (Dermatophagoides farinae) ≥ class 2 in radioallergosorbent test (RAST).
- BHR (i.e., a decrease in FEV1 of at least 20%) measured by methacholine challenge.
- FEV1 ≥ 75% of predicted value (according to height, weight and sex).
- Subject must demonstrate a significant EAR and LAR without rescue medication use within the first 7 hours after BAP.
- No clinically relevant abnormalities in 12-lead ECG at screening.
Exclusion Criteria:
- Severe, unstable bronchial asthma.
- Exacerbation of asthma ≤ 4 weeks prior to screening.
- Treatment with parenteral and oral corticosteroids 6 weeks prior to screening and during the study.
- Treatment with inhaled corticosteroids, methylxanthines (e.g., theophyllin), anticholinergics (e.g., ipratropium bromide), leukotriene modifiers (e.g., montelukast), tiotropium bromide, cromolyn or nedocromil within 2 weeks prior to screening and during the study.
- Current treatment with any immunosuppressants (e.g., monoclonal antibodies, methotrexate, cyclosporin).
- Specific immunotherapy (SCIT) to mite within 3 years prior to screening.
- Serious adverse drug reaction to previous biological treatment.
- Previous therapy with a mAb targeting CD4, including tregalizumab.
- Known hypersensitivity to any constituents of tregalizumab and/or other mAbs, that, in the opinion of the investigator or Medical Monitor, contraindicates participation.
- Previous inclusion in this study.
- Serum transaminases, ALAT and/or ASAT > 2.5-fold ULN at screening.
- Bilirubin > 34.2 µmol/L at screening.
- AP > 2-fold ULN at screening.
- Urea nitrogen > 1.5-fold ULN at screening.
- Kidney insufficiency as defined by creatinine level > 133 µmol/L at screening.
- History of severe allergic or anaphylactic reaction to proteins of human origin (e.g. vaccination reaction, biological therapy).
- Presence or history of malignancy within the previous 5 years (except completely resected squamous or basal cell carcinoma of the skin).
- Presence or history of clinically significant major disease (e.g., severe heart/lung disease New York Heart Association [NYHA] Class ≥ 3, autoimmune disease [apart from rheumatoid arthritis], acute uncontrolled hyper- or hypo-thyroidism, severe uncontrolled hypo or hypertension).
- Serious local (e.g., abscess) or systemic (e.g., pneumonia, septicemia) infection or recurrent chronic infections within 6 weeks prior to screening visit or during the screening period.
- Any infection requiring antibiotic therapy by any route of administration within 4 weeks prior to screening.
- Vaccination with live, live attenuated, and/or killed vaccines in the 12 weeks prior to the first administration of the study drug and during the study.
- Positive diagnosis for acute or chronic infections (e.g. HCV, HBV, HIV) at screening or history of previous chronic infection.
- Acute or clinically symptomatic EBV (infectious mononucleosis) or CMV infection.
- Presence or history of latent or active tuberculosis.
- Known immune deficiency.
- Presence or history of lymphoproliferative disease, including lymphoma and lymphadenopathy.
- Presence or history of clinically significant drug or alcohol abuse.
- Employee at study site or any institution involved in this study (including the sponsor), or spouse/partner or relative of an investigator.
- Pregnant or nursing woman or woman considering to become pregnant during the study or in the 3 months after the last administration of study drug.
- Woman of childbearing potential (unless surgically sterile or post-menopausal > 52 weeks) who is not using two (2) independent effective contraceptive methods (e.g., oral or injectable contraceptives, intra-uterine devices, double barrier method, contraceptive patch or female sterilization) during the study and for at least 3 months after the last administration of study drug OR Non-vasectomized man who, during the study or in the 3 months after the last administration of study drug, is not using two (2) independent effective contraceptive methods (as specified above) or is planning a sperm donation.
- Donation of blood within 30 days prior to screening until end of study.
- Participation in another clinical trial within 90 days before screening or during the study.
- Inability or lacking motivation to adhere to the study requirements and to comply with the study schedule.
- Imprisonment or placement in an institution (AMG § 40 (1), sentence 4).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tregalizumab
|
a monoclonal antibody designed for the treatment of allergic asthma indication
|
Placebo Comparator: Matched placebo
|
Matched Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Baseline-corrected late asthmatic response measured by the area under the curve for the forced expiratory volume (FEV1) at 4 to 7 hours after bronchial allergen provocation
Time Frame: Day 84
|
Day 84
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in late asthmatic response, as measured from 4 to 7 hours after bronchial allergen provocation by the maximum decrease in the normalized forced expiratory volume (FEV1) values
Time Frame: Baseline and Day 84
|
Baseline and Day 84
|
Change in early asthmatic response, as measured from 0 to 3 hours after bronchial allergen provocation by the maximum decrease in the normalized forced expiratory volume (FEV1) values
Time Frame: Baseline and Day 84
|
Baseline and Day 84
|
Change in early asthmatic response, as measured from 0 to 3 hours after bronchial allergen provocation by the area under the curve of the normalized forced expiratory volume (FEV1) values
Time Frame: Baseline and Day 84
|
Baseline and Day 84
|
Fraction of eNO (FeNO) absolute levels and delta increase after bronchial allergen provocation
Time Frame: Baseline and Day 84
|
Baseline and Day 84
|
Dose of methacholine causing a decrease in forced expiratory volume (FEV1) of at least 20% (PD20)
Time Frame: Baseline, Day 85, Day 112
|
Baseline, Day 85, Day 112
|
Impact of tregalizumab on TH1, TH2 and TH17 cytokines in blood
Time Frame: Baseline, Day 1, Day 85
|
Baseline, Day 1, Day 85
|
Impact of tregalizumab on TH1, TH2 and TH17 cytokines and T-cell transcription factors in sputum
Time Frame: Day 1 until Day 85
|
Day 1 until Day 85
|
Number of eosinophils, neutrophils, macrophages and lymphocytes in sputum
Time Frame: Day 1 until Day 85
|
Day 1 until Day 85
|
Eosinophil cationic protein (ECP) concentration in sputum
Time Frame: Day 1 until Day 85
|
Day 1 until Day 85
|
Number of eosinophils in blood
Time Frame: Baseline, at Day 1, Day 84 and Day 85
|
Baseline, at Day 1, Day 84 and Day 85
|
Change in mite-specific IgE, IgG4, total IgE and IgG levels in blood
Time Frame: Baseline and Day 84
|
Baseline and Day 84
|
Impact of tregalizumab on the expression of markers of PBMC lineage in blood
Time Frame: Baseline until Day 112
|
Baseline until Day 112
|
Incidence and severity of adverse events (AEs) in the participants
Time Frame: Approximatively 27 weeks (study duration)
|
Approximatively 27 weeks (study duration)
|
Levels of specific anti-tregalizumab antibodies in blood
Time Frame: Day 1, Day 36, Day 84
|
Day 1, Day 36, Day 84
|
Number of rescue ß2-agonist puffs used
Time Frame: Approximatively for 27 weeks
|
Approximatively for 27 weeks
|
Change of VAS Nasal Symptom Score
Time Frame: Baseline and Day 84
|
Baseline and Day 84
|
Quality of life assessed with Asthma Control Test (ACT) and Asthma Quality of Life Questionnaire for 12 years and older (AQLQ+12)
Time Frame: Baseline and Day 84
|
Baseline and Day 84
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Stefan Zielen, Prof. Dr., Medaimun GmbH
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OG-061-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergic Asthma
-
University of ZurichUniversity of AarhusActive, not recruitingAllergic Rhinitis Due to Grass Pollen | Allergic Rhinitis | Rhinitis, Allergic, Seasonal | Allergic Asthma | Rhinitis; Allergic, With AsthmaSwitzerland
-
Children's Mercy Hospital Kansas CityCompletedAsthma | Allergic Asthma | Non-allergic AsthmaUnited States
-
ALK-Abelló A/SCompletedAllergic Rhinitis Due to House Dust Mite | Allergic Asthma Due to Dermatophagoides Farinae | Allergic Asthma Due to Dermatophagoides PteronyssinusPoland, United Kingdom, Spain, United States, Russian Federation, Hungary, France, Bulgaria, Germany
-
ALK-Abelló A/SITEC ServicesCompletedAllergic Rhinitis Due to House Dust Mite | Allergic Asthma Due to Dermatophagoides Farinae | Allergic Asthma Due to Dermatophagoides PteronyssinusFrance
-
The Cleveland ClinicEnrolling by invitation
-
Leti Pharma GmbHCompletedAllergic Asthma | Allergic RhinoconjunctivitisGermany
-
University Hospital, AkershusOslo University Hospital; ImmunoPharma ASRecruitingAllergic Asthma | Allergic Rhinoconjunctivitis | Immune ToleranceNorway
-
Inmunotek S.L.BioClever 2005 S.L.; NTS hub S.LNot yet recruitingPerennial Allergic Rhinitis | Allergic Asthma | Allergic Rhinoconjunctivitis | House Dust Mite AllergySpain
-
Johann Wolfgang Goethe University HospitalCompleted
-
University of North Carolina, Chapel HillNational Institutes of Health (NIH)TerminatedMild Allergic Rhinitis | Mild Allergic Rhinitis With Mild AsthmaUnited States
Clinical Trials on Tregalizumab
-
BiotestAbbVieTerminatedRheumatoid ArthritisUnited States, Bulgaria, Canada, Czechia, Estonia, Germany, Hungary, Lithuania, Mexico, Poland, Russian Federation, Serbia, Slovakia, Ukraine